Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer

Despite remarkable initial responses of anaplastic lymphoma kinase (ALK) inhibitors in ALK-positive non-small cell lung cancer (NSCLC) patients, cancers eventually develop resistance within one to two years. This study aimed to compare the properties of iruplinalkib (WX‑0593) with other ALK inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yingying, Zheng, Qingmei, Wang, Xinmei, Zhao, Shuyong, Huang, Wenshu, Jia, Linchao, Ma, Cuicui, Liu, Shicong, Zhang, Yongpeng, Xin, Qianqian, Sun, Yan, Zheng, Shansong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140010/
https://www.ncbi.nlm.nih.gov/pubmed/37036582
http://dx.doi.org/10.1007/s10637-023-01350-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140010/
https://www.ncbi.nlm.nih.gov/pubmed/37036582
http://dx.doi.org/10.1007/s10637-023-01350-x

Ejemplares similares